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Background: Chronic kidney disease (CKD) is common and increasing in prevalence. Cardiovascular disease (CVD)
is a major cause of morbidity and death in CKD, though of a different phenotype to the general CVD population.
Few therapies have proved effective in modifying the increased CVD risk or rate of renal decline in CKD. There are
accumulating data that aldosterone receptor antagonists (ARA) may offer cardio-protection and delay renal
impairment in patients with the CV phenotype in CKD. The use of ARA in CKD has therefore been increasingly
advocated. However, no large study of ARA with renal or CVD outcomes is underway.
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Methods: The study is a prospective randomised open blinded endpoint (PROBE) trial set in primary care where
patients will mainly be identified by their GPs or from existing CKD lists. They will be invited if they have been
formally diagnosed with CKD stage 3b or there is evidence of stage 3b CKD from blood results (eGFR 30–44 mL/min/
1.73 m2) and fulfil the other inclusion/exclusion criteria. Patients will be randomised to either spironolactone 25 mg
once daily in addition to routine care or routine care alone and followed-up for 36 months.
Discussion: BARACK D is a PROBE trial to determine the effect of ARA on mortality and cardiovascular outcomes (onset
or progression of CVD) in patients with stage 3b CKD.
Trial registration: EudraCT: 2012-002672-13
ISRTN: ISRCTN44522369
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Chronic kidney disease (CKD) is increasingly common, af-
fecting around 6% of the UK population [1,2], associated
with an age-related decline in renal function that is accel-
erated in hypertension, diabetes mellitus, obesity, and pri-
mary renal disorders [3]. While this high (and rising [4])
prevalence is in part due to the ageing population, it is also
a result of increases in hypertension and diabetes mellitus.
CKD is defined and categorised in to five stages using esti-
mated glomerular filtration (eGFR) as well as evidence of
renal damage (imaging or proteinuria) in the early stages
[5]. The largest group, with over 90% of cases, is estimated
to be CKD stage 3 with 84% stage 3a (eGFR of 45 to
59 mL/min/1.73 m2 [2]) and 16% stage 3b (eGFR of 30 to
44 mL/min/1.73 m2 [6]). Population studies have used the
four-variable modification of diet in renal disease (MDRD)
formula to determine eGFR [7]. In patients aged 65 or
over, up to 35% have an eGFR of less than 60 mL/min/
1.73 m2 [8]. CKD prevalence appears to be increasing.
Data from the American National Health and Nutrition
Examination Survey determined that in the period 1999 to
2004 the overall prevalence of CKD stages 1 to 4 increased
significantly when compared to the survey period 1988 to
1994 (13.1% versus 10.0%) [4,9,10].
CKD is a major cause of increased mortality and mor-
bidity through increased vascular events and progression
to end stage renal failure (ESRF) [11]. These increased
events result in CKD incurring a high cost to healthcare
systems, with the dialysis required in ESRF benchmarked
at the maximum acceptable cost effectiveness threshold
for an intervention by most healthcare systems. How-
ever, the most important component of CKD in terms of
mortality and morbidity is cardiovascular disease (CVD)
[12]. There is a graded inverse relationship between car-
diovascular risk and eGFR, independent of age, sex, and
other risk factors [4,13-15]. While the CVD risk in ESRF
is high, the healthcare burden resides in early stages of
disease as it is more prevalent, affecting around 35% of
those aged over 70 years [16].Although the risk of coronary artery disease is in-
creased in CKD, the pattern of CVD is atypical, with a
much greater incidence of heart failure and sudden
cardiac death than in the general CVD population
[17-19]. The main pathological features in CKD that
appear to determine this particular cardiovascular risk
phenotype are: i) left ventricular (LV) hypertrophy and
fibrosis accompanied by both systolic and diastolic
dysfunction, and ii) arterial wall thickening, stiffening,
and calcification (atherosclerosis). Therefore, although
patients with CKD also suffer typical patterns of CVD
(coronary and peripheral artery atherosclerosis), the
excess rates of cardiovascular events in CKD appear to
relate more to vascular wall and ventricular changes
than to atherosclerosis.
Given this particular vascular pathophysiology, it is un-
surprising that conventional cardiovascular risk factors are
less predictive of outcomes in CKD than in the general
population [20], and less predictive than eGFR and protein
excretion [13,15,21], even after controlling for variables
such as blood pressure [22]. The 2014 draft update
National Institute for Health and Care Excellence (NICE)
guidelines for CKD [23] are unable to agree a specific risk
assessment tool for patients with CKD stage 3 or above.
Furthermore, interventions to reduce the increased car-
diovascular risk in CKD have proved disappointing, with
only limited evidence for traditional therapies in terms of
cardiovascular outcomes.
For example, the SHARP (Study of Heart and Renal
Protection) trial [24] aimed to assess the safety and effi-
cacy of reducing LDL cholesterol in more than 9,000 pa-
tients with CKD with a low dose of a statin (simvastatin
20 mg daily) and ezetimibe. The trial showed that lower-
ing of LDL cholesterol safely reduced the risk of major
atherosclerotic events in patients with CKD. However,
the reduction in non-fatal myocardial infarction or cor-
onary death was not significant.
Alternative treatment options to provide protection
from vascular events or delay progression of CKD are
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burden of the disease.
Rationale
CKD is common and increasing in prevalence. CVD is a
major cause of morbidity and death in CKD, though of
a different phenotype to the general CVD population.
Currently, few therapies have proved effective in modify-
ing the increased CVD risk or the rate of renal decline
in CKD. There are accumulating data that aldosterone
receptor blockers (ARA) may offer cardio-protection
and delay renal impairment in patients with CKD.
There are recent data that indicate beneficial effects of
ARA therapy on surrogate markers for CVD risk in pa-
tients with CKD, i.e., not just in those with established ad-
vanced CVD such as heart failure. This is important
because there are presently limited therapeutic options to
reduce overall cardiovascular risk in CKD, with modest ef-
fects of LDL reduction shown in the recent SHARP study
[24] and sub-studies of large angiotensin-converting-
enzyme (ACE) inhibitor and statin trials only suggesting
limited cardiovascular benefits in patients with early stage
CKD [25,26].
The Birmingham CRIB-2 study, in which two of the
present authors were involved (CF & JT), recently showed
that the ARA spironolactone provided significant benefi-
cial effects on validated intermediate cardiovascular end-
points of prognostic value, including LV mass and arterial
stiffness [27]. In a placebo-controlled, double-blind trial
112 patients with stage 2 and 3 CKD with good blood
pressure (BP) control on established treatment with ACE
inhibitors or Angiotensin II Receptor Blockers (ARB) were
treated in an active run-in phase with spironolactone
25 mg once daily and then randomised to continue spir-
onolactone or to receive a matching placebo. Compared
with placebo, the use of spironolactone resulted in highly
significant reductions in LV mass and arterial stiffness
(pulse wave velocity, augmentation index, and aortic dis-
tensibility), and improved myocardial diastolic function
and collagen turnover [27]. These clinical findings were
attributed to a reduction in arterial and myocardial in-
flammation and fibrosis but may also be a function of
the considerable human and animal evidence base that al-
dosterone receptor antagonism improves endothelial-
dependent vasodilatation and vascular nitric oxide bio-
activity [28]. Further, recent data have shown that ARA
therapy in non-diabetic CKD haemodialysis patients pre-
vented progression of carotid intima-media thickness [29].
These recent clinical data on the effect of ARA on inter-
mediate vascular outcomes have resulted in calls for de-
finitive trials [30,31].
ARA therapy might therefore be an effective candidate
for improved cardiovascular outcomes, through the pre-
vention of aldosterone-mediated vascular endothelialdysfunction as well as widespread cardiovascular inflam-
mation, fibrosis, and hypertrophy. Since spironolactone is
well recognised as an effective anti-hypertensive agent for
patients with hypertension, even when this is resistant to
other drugs [32], the intensive phenotyping of blood pres-
sure, LV function, and arterial stiffness in the Benefits
of Aldosterone Receptor Antagonism in Chronic Kidney
Disease (BARACK D) trial will enable modelling of the ex-
tent to which any positive results may be explained by any
BP differences between study arms. The 25 mg dose of
spironolactone used in BARACK D, and most clinical tri-
als in which it has been involved, is similar to that used in
hypertension and heart failure cases which are states char-
acterised by excess cardiovascular risk and with a high
probability of co-morbid CKD.
Choice of comparators
Blockade of the renin-angiotensin-aldosterone system by
ACE inhibitors and ARBs has shown mortality benefit in
patients with chronic heart failure and in those with, or
at high risk of, coronary artery disease [25,33,34]. The
benefits are attributed to prevention of the multiple ad-
verse effects (AEs) of angiotensin II. ACE and ARB’s ap-
pear superior to other BP lowering drugs in slowing the
progression of CKD, though the effect may be marginal
[33]. These agents are therefore widely recommended in
international guidelines [35-37] as ‘reno-protection’ for
CKD patients, especially those with proteinuria or dia-
betes mellitus.
Aldosterone may also be an important mediator of car-
diac and vascular damage in many disease states. Mineralo-
corticoid receptors are present in many tissues, including
the brain, heart, and blood vessels, as well as the kidney,
and there is aldosterone production within these tissues
[38]. These receptors may also be activated by circulating
glucocorticoids in the presence of oxidative stress [39].
Local mineralocorticoid receptor activation by aldosterone
leads to numerous pathological effects on the cardiovascu-
lar system including endothelial injury, inflammation, oxi-
dative stress, and fibrosis in the heart and vasculature, as
well as the development of hypertension and autonomic
dysfunction [38,40,41].
Rationale for ARA intervention to reduce cardiovascular
events
In humans, primary aldosteronism is associated with a
greater LV mass and higher risk of adverse cardiovascular
events than control hypertensive populations and, in pa-
tients after myocardial infarction, plasma aldosterone con-
centration within the normal range predicts an adverse
prognosis [42-44]. A recent study of subjects undergoing
coronary angiography confirmed an independent associ-
ation of plasma aldosterone levels with total and cardio-
vascular mortality [45].
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cause of a perceived risk of azotaemia and hyperkalaemia,
though similar restrictions were applied to ACE inhibitors
until outcome data were reported. There are, however, ac-
cumulating data on combined treatment with ACE and
ARA to improve renal function in patients with CKD [46].
From a safety perspective, even oligoanuric haemodialysis
patients can tolerate spironolactone in low doses [47].
Objectives
Primary objective
To determine the effect of ARA on mortality and cardio-
vascular outcomes (onset or progression of CVD) in pa-
tients with stage 3b CKD.
Secondary objectives
To determine the effect of ARA in patients on measures
of: cardiovascular haemodynamics; LV function; decline
in renal function; treatment costs and benefits; and inci-
dence of transient ischaemic attack; and to determine
the safety of ARA in patients with stage 3b CKD.
Intensively phenotyped group
To determine the effect of ARA in patients on measures
of cardiovascular haemodynamics.
Trial design
A prospective, randomised, open, blinded endpoint
(PROBE) trial: eligible patients, from 120 practices re-
cruited by 6 National Institute for Health Research School
for Primary Care Research departments in addition to a
specialist renal trial recruitment group, with previously re-
corded blood test results suggesting CKD stage 3b will be
invited to take part in the study and randomised to either
spironolactone 25 mg once daily in addition to routine
care or routine care alone. BP in both groups will be ti-
trated (monitored and adjusted accordingly) by the clini-
cians against NICE guideline standards and checks of
electrolytes undertaken.
A subgroup of participants will form the intensively
phenotyped group in whom 24-h BP and arterial stiff-
ness will be monitored in detail to enable modelling of
the extent to which positive results may be explained by
any BP differences between study arms. The secondary
endpoints assessed in the intensively phenotyped group
will determine the effect of ARA on 24-h BP and pulse
wave velocity.
Methods
The study is set in primary care where patients will pri-
marily be identified opportunistically by their primary
care clinician or systematically from existing CKD lists.
They will be invited if they have been formally diagnosed
with CKD stage 3b or there is evidence of stage 3b CKDfrom blood results (eGFR 30–44 mL/min/1.73 m2 [2])
and fulfil the other inclusion/exclusion criteria.
Potentially eligible patients will be invited to attend a
baseline clinic at their own practice where the trial will
be explained. Informed consent will be obtained and
baseline assessments performed.
A subset of patients will form the intensively pheno-
typed group who will undergo additional trial proce-
dures as described below and in the procedure schedule
shown in Table 1. The intensive phenotyping of 24-h BP
and arterial stiffness in BARACK D will enable model-
ling of the extent to which any positive results may be
explained by any BP differences between study arms.
Eligibility criteria
Inclusion criteria
Participants must fulfil all of the following:
 Participant is willing and able to give informed
consent for participation in the study.
 Male or female, aged 18 years or above.
 Evidence of stage 3b CKD using the MDRD
equation on at least two occasions, whether or not
on the practice chronic disease register.
 Able (in the recruiting clinician’s opinion) and
willing to comply with all study requirements.
 Willing to allow his or her General Practitioner and
consultant, if appropriate, to be notified of
participation in the study.
 Willing to provide contact details to the research
team (encompassing recruitment centre and practice
staff ), for use at any time should the need arise, on
trial-related matters.
 If the participant is a female of child-bearing
potential, they are willing to ensure effective
contraception during the trial period.
Exclusion criteria
The participant may not enter the study if ANY of the
following apply:
 Female participants who are pregnant, lactating, or
planning pregnancy during the course of the study.
 Type 1 diabetes mellitus.
 Terminal disease or felt otherwise unsuitable by
their research clinician.
 Clinical diagnosis of chronic heart failure or known
LV systolic dysfunction with ejection fraction ≤ 40%.
 Recent myocardial infarction (within 6 months).
 Alcohol or drug abuse.
 Suspected or known current hazardous or harmful
drinking, as defined by an alcohol intake of greater
than 42 units every week.
 Suspected or known current substance misuse.
Table 1 BARACK D patient visit schedule
Treatment and follow-up
Week B 0 1 2 4 12 26 39 52 65 78 91 104 117 130 143 156
Visit V V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14 V15
Valid informed consent x Randomisation in absentia
and prescription produced
once blood results received
Full demographic details x
Medical history x x
Clinical history x
Concomitant medications x x x x x x x x
Weight, height, waist/hip x x
Physical examination x
Office blood pressure measurement x x x x x x x x x x x x x x x x
Home blood pressure measurement x x x x x x
KDQOL-SF questionnaire* x x x x x
QoL EQ-5D-5 L questionnaire* x x x x x
ICECAP-A questionnaire* x x x x x
QoL VAS* x x x x x
Diary card (medication monitoring) x x x x x x x x
Diary card (Health Economics) x x x x x x x x x x x x x
Adverse event monitoring x x x x x x x x x x x x x x x x
Urine albumin/creatinine ratio x x
12 lead ECG x x
Blood tests for:
Full blood count x x
Renal profile x x x x x x x x x x x x x x x x
Liver function test and bone profile x x x x x
Lipids x x x x x
HbA1c x x x x x
Fasting blood sugar x x x x x
B-type natriuretic peptide x x x x x
Future analysis (where applicable) x x x x
Intensively phenotyped group
only
Pulse wave velocity x x x x x
24-h ambulatory blood pressure
estimation
x x x x x
*Kidney Disease Quality of Life-Short Form (KDQOL-SF), Quality of Life EuroQol, 5 Dimensions, 5 Levels (QoL EQ-5D-5 L) ICEpop CAPability measure for Adults
(ICECAP-A), Quality of Life Visual Analogue Scale (QoL VAS).
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be spurious, or intolerance of spironolactone.
 Serum potassium at baseline over 5 mmol/L.
 Documented Addisonian crisis and/or on
fludrocortisone.
 Documented symptomatic hypotension or baseline
systolic BP under 100 mmHg.
 Recent acute kidney injury or admission for renal
failure.
 Albumin/creatinine ratio (ACR) >70 mg/mmol.
 Prescription of medications with known harmful
interactions with spironolactone as documented inthe British National Formulary including tacrolimus,
lithium, and cyclosporine.
 Any other significant disease or disorder which, in the
opinion of the recruiting clinician, may either put the
participants at risk because of participation in the
study, or may influence the result of the study, or the
participant’s ability to participate in the study.
Interventions
Spironolactone has been selected as the trial ARA, to be
used in the “Standard Care + Spironolactone” arm, since
it has a large evidence base for effective treatment in
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data from these trials on the drug’s renal safety in high-
risk cardiovascular populations. Spironolactone is also
the most cost effective ARA available as a generic pre-
scription. Clinical trial labelling will therefore not be re-
quired in accordance with Article 14 of the EU clinical
trial directive.
Spironolactone 25 mg will be prescribed as a standard
NHS FP10 prescription by the study recruiting research
clinician using the recruitment sites’ local pharmacies,
processes, and systems, also removing the requirement
for trial-specific drug accountability mechanisms to be
in place. As such, there will be no trial-specific study
treatment requirements. The trial treatment regime will
be 25 mg spironolactone once daily for the duration of
the trial.
Modifications
Safety monitoring will include the following discontinu-
ation rules:
Hyperkalaemia
In RALES, incidence of serious hyperkalaemia was 2%
although patients with a creatinine of >221 μmol/L were
excluded [22]. In EPHESUS, Eplerenone caused a
K+ >5.5 mmol/L in 10% of patients with an eGFR
of <70 mL/min [38]. In CRIB-2 [48], during the open
label run, only one patient was withdrawn due to hyper-
kalaemia (K+ >6.5) – with results later shown to be
spurious – and six had a K+ of >5.5 mmol/L requiring
dose reduction to alternate days. During the double-
blind phase only two patients on ARA and two on pla-
cebo had a K+ of >5.5 mmol/L. For BARACK D, serum
K+ and creatinine will be checked at all visits. Patients
will stop trial medication if systemically unwell due to
intercurrent infection, diarrhoea, or need for surgical
intervention for any reason. The study drug will be re-
started one week after the recruiting research clinician
is satisfied recovery has taken place; serum K+ and cre-
atinine will be rechecked at weeks 1 and 2 following re-
sumption. The protocol below will be followed in the
event of hyperkalaemia:
 Serum potassium below 5.4 mmol/L, no action;
 Between 5.5–5.9, reduce dose to 25 mg alternate days;
 6.0–6.4 stop study drug and restart after 7 days on
alternate days and if remains over 6.0 withdraw
patient from trial treatment;
 >6.5 appropriate management and withdraw patient
from trial treatment.
Deterioration of renal disease
If there is a deterioration of 20% in eGFR between suc-
cessive visits then trial treatment will be withdrawn andspecialist care referral made. Patients will also be with-
drawn if there is a reduction in eGFR of 25% from their
baseline eGFR, or an increase in creatinine of 30% over
the baseline value.
Hypotension
If there is >20 mmHg systolic postural drop in BP with
symptoms during the trial and/or the systolic BP drops
to below 100 mmHg, then the trial medication will be
discontinued.
If withdrawn from the trial, the reason for withdrawal
will be recorded on the trial withdrawal form and if due to
an AE, the research team will arrange for follow-up visits
or telephone calls until the AE has resolved or stabilised.
Adherence
Study treatment compliance will be self-monitored
throughout the trial using a medication monitoring diary
card. For participants assigned to the spironolactone treat-
ment arm if compliance cannot be verified through patient
report, prescription uptake will also be verified by the
patient’s research clinician through database searches of
prescription collection.
Concomitant care
If participants on the spironolactone arm develop medical
conditions which require treatment with medications
known to have harmful interactions with spironolactone
as listed in the British National Formulary, then their pre-
scription will be halted [49] but follow-up will continue.
Throughout the trial the participant remains the re-




Time from randomisation until the first occurring death,
first onset, or hospitalisation for heart disease (coronary
heart disease, arrhythmia, new onset/first recorded atrial
fibrillation, sudden death, failed sudden death), stroke, or
heart failure. Primary endpoints will be adjudicated by an
independent Endpoint Committee blinded to the treat-
ment arm.
Secondary endpoints
 Change in BP annually and at final visit
 Rates of hypotension (<100 mmHg systolic or
>20 mmHg systolic drop on standing)
 Changes in B-type natriuretic peptide (BNP)
 Change in urine ACR
 Changes in eGFR
 Change in health-related quality of life on EQ-5D-
5 L, ICECAP-A, and QoL-VAS
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 Transient ischaemic attack – as defined by the
American Heart Association (2009) [50]
 Rates of AEs
 Rates of hyperkalaemia
Intensively phenotyped group
 Mean change in ambulatory BP from randomisation
to final visit (measured in mmHg)
 Change in carotid-femoral pulse wave velocity from
baseline to final visit
Participant timeline
Following consent, all patients will have the following
information taken and investigations performed at the
initial visit: patient demographics, physical examination
(height, weight, waist circumference), office BP measure-
ment using a British Hypertension Society validated au-
tomated device after 5 minutes rest, venepuncture for
routine haematology, and biochemistry including renal
function (including eGFR calculated using MDRD and
CKD-EPI formulae, hepatic and bone profiles, full blood
count, fasting blood sugar, HbA1c, lipids, and BNP),
urinalysis using ACR, 12 lead electrocardiograph, and
quality of life questionnaires (EQ-5D-5 L, KDQOL-SF,
ICECAP-A, and QoL VAS questionnaires). In addition
to a diary card to monitor side effects of trial medica-
tion, pregnancy tests will be performed on women of
childbearing potential, if deemed necessary, at the dis-
cretion of the research clinician.
In the intensively phenotyped group only:
 24-h ambulatory BP estimation
 Pulse wave velocity measured with cardiovascular
software, using a validated applanation tonometry
device [51]
Following the baseline visit, as with all laboratory ana-
lyses returned to the recruitment site under routine care,
blood results will be reviewed promptly to ensure safety
and eligibility.
Once eligibility is confirmed, the research clinician will
randomise the patient (by accessing the Primary Care
Clinical Trial Unit’s (PC-CTU) in-house online random-
isation system “Sortition” to obtain the randomisation
code), produce the necessary prescription if applicable,
issue the patient where necessary, and book an appoint-
ment for the patient to return for the next visit after taking
spironolactone for 7 days or 7 days following randomisa-
tion where assigned to the routine care arm.
Subsequent assessments
Subsequent assessment will continue for both treatment
arms for a further 36 months with follow-up visits atweeks 1, 2, 4, 12, 26, and then every 13 weeks to
156 weeks. Windows either side of the visits will be
2 days for V1 and V2, 4 days at V3 and V4, 7 days for
V5, and 2 weeks thereafter (all calculated from date of
randomisation). Patients will also be flagged with the Of-
fice for National Statistics for long-term follow-up of
mortality, with initial assessment at 5 years. Measure-
ments at each follow-up visit will vary according to the
schedule in Table 1.
Patients will also be supplied with a validated home
BP monitoring machine, along with an additional diary
card and an instruction sheet, for 1 week every 6 months,
to document their self-assessed BPs. They will take 2
readings twice daily, i.e., 2 each morning and 2 each
evening over the week. The readings for the first 2 days
will be discarded and the mean of the remaining read-
ings taken as the home BP level.
Clinicians will be strongly encouraged to manage BP
according to NICE CKD guidelines [37].
Definition of end of trial
The end of trial will be defined as the date of the last
visit for the last participant for the initial 3 year follow-
up period. The trial will have an independent Trial
Steering Committee (TSC) and Data Monitoring and
Ethics Committee (DMEC) who will assess the study
feasibility as the trial progresses and will have ‘stop rule’
authority to advise early termination of the trial in the
event of safety concerns or futility either through poor
recruitment, lack of events, or lack of any treatment ef-
fect. These ‘stop rules’ will be defined fully by the
DMEC. A formal futility and feasibility analysis will be
performed at 12 months by the DMEC to assess recruit-
ment and retention which will determine whether cri-
teria for the trial to proceed have been met.
Discontinuation/withdrawal of participants from study
treatment
Each participant has the right to withdraw from the
study at any time in line with the following criteria:
1. Withdrawal from treatment (follow-up continued)
2. Complete withdrawal from trial excluding notes
review (without participant involvement)
3. Complete withdrawal
4. In addition, the recruiting research clinician may
discontinue a participant from the study treatment at
any time if it is considered necessary for any reason.
In all cases, where possible, follow-up and inclusion in
the intention-to-treat analysis, will continue.
Sample size
A UK representative spread of practices will be achieved
by stratifying practice postcode location into quartiles of
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agree to take part sequentially until each deprivation
quartile practice target is reached. The estimate for the
CVD event rate (defined by hospitalisation for coronary
heart disease, heart failure, ischemic stroke, and periph-
eral arterial disease) and total mortality rate in patients
with CKD stage 3b being 11.29 and 4.76 per 100 person
years, respectively, gives a combined event rate of 16.05
per 100 person years [12]. To detect a 20% relative risk
reduction in death or cardiovascular events within
3 years in the intervention group as compared with the
control group (i.e., hazard ratio = 0.8) with a two-sided
significance of 0.05, 1,308 participants per arm are re-
quired seeking 90% power and assuming 10% drop out
rate per year.
Recruitment
Potential subjects will be identified by searching routine
electronic clinical records for patients with biochemical
evidence of CKD stage 3b (eGFR 30–44 mL/min/1.73 m2
[2]). The recruitment site will then send out an invitation
letter inviting the patients to attend a baseline assessment
and eligibility visit. A reply slip, pre-paid envelope, and al-
ternative contact details (e.g., e-mail address and phone
number) will be provided for expressions of interest.
For the average GP practice, 180 patients are likely to
meet stage 3b CKD criteria. Assuming that around 80%
of these patients are eligible and at least 50% of these
are willing to take part (based on our experience recruit-
ing to heart failure studies which have a similar age dis-
tribution as patients with CKD), then 72 patients may be
recruited per practice, requiring 37 practices in total, but
increased to 60 to allow for poor recruiting practices, or
15 practices per Townsend quartile of deprivation. To
improve the representativeness of the trial population,
the number of practices per recruiting centre will be
increased to 20 with the intention of reducing these
numbers by 50% and giving 30 practices per Townsend
quartile of deprivation.
Sequence generation
Block randomisation with randomly varying block size
will be performed in line with PC-CTU standard operat-
ing procedures (SOPs) and will be via the internet.
Concealment mechanism
Randomisation will be performed using Sortition, PC-
CTU’s in-house online randomisation system. It sup-
ports multiple studies and sites, a range of randomisation
algorithms (simple, block, stratified and minimised), un-
balanced allocation ratios, blind or open trials, email noti-
fications, and site package statistics (for blind trials). It is
secure, provides full audit logs, and has been validated at
algorithm and interface levels.Implementation
All patients who give consent for participation and who
fulfil the inclusion criteria will be randomised. The staff
member responsible for recruitment will request random-
isation from the PC-CTU via a web interface. Patients will
be randomised to treatment with spironolactone 25 mg
once daily prescribed on top of routine care or to continue
with routine care alone.
Blinding
BARACK D is a PROBE trial where neither the patients
nor research clinicians are blinded to the trial treatment.
However, an independent Endpoint Committee, blinded
to the treatment arm, will assess the primary endpoints.
Emergency unblinding
Not applicable as recruitment site remains unblinded.
Data collection
Source documents will include:
 Primary care electronic and paper records/outputs
 Reports from laboratory investigations
 Hospital correspondence
 Records of 24-h ambulatory and home BP
measurements
 Patient questionnaires
 Patient diary cards
 The case report form (CRF) itself where there is no
other written or electronic record of data
Clinical trial data is collected by the PC-CTU both
electronically and in paper format, with a paper back-up
for the data captured electronically.
All documents will be stored safely in confidential con-
ditions according to PC-CTU policies and SOPs. On all
study-specific documents, other than the signed consent,
the participant will be referred to by the study participant
number/code, not by name. Study documentation will be
archived for a period of 5 years according to PC-CTU
SOPs.
Source data will be verified as appropriate by the PC-
CTU Quality Manager or delegate using a risk-based ap-
proach and will be defined in the monitoring plan.
Data management
All data management functions will be performed in
line with PC-CTU SOPs. A Data Management Plan is in
place for all PC-CTU studies outlining in detail the
study specific procedures that are in place to ensure that
high quality data are produced for statistical analysis.
The Data Management Plan is reviewed and signed by
all applicable parties including the trial manager and the
trial statistician prior to the first patient being enrolled.
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The primary outcome will be analysed using Cox
proportional-hazards method, adjusting for practices. Re-
sults will be presented as hazard ratios with 95% confi-
dence intervals and associated two-sided P values. To test
the robustness of the result, a sensitivity analysis will be
carried out, using the same method, adjusting the follow-
ing pre-specified baseline prognostic factors: diastolic and/
or systolic BP above or below current NICE target, type II
diabetes, and coronary artery disease.
The same approach will be repeated for individual
components of the primary composite endpoint and all-
cause mortality as secondary analyses. Analyses for other
outcomes will be carried out using multiple log-binomial
regression models for binary data and linear mixed effect
model for continuous data collected over time.
Assumption of proportional hazards will be examined
and if any of the assumptions were violated, a suitable
alternative survival method will be considered. Similarly,
alternative methods will be considered if any violation of
assumptions is detected in any of the aforementioned
methods for other outcomes.
AEs will be tabulated according to randomised group
assignments and the proportions will be compared using
Fisher’s exact test.
The primary analyses will be conducted on all rando-
mised participants, applying the principle of intention-
to-treat, as far as is practically possible, given any miss-
ing data. Specifically, the participants will be analysed in
the groups to which they were allocated.
The missing at random assumption will be tested as far
as is possible by analysing each baseline covariate in a re-
gression model to determine which, if any, are associated
with missingness. All baseline covariates are expected to
be observed. Baseline values will be summarised for those
who did and did not complete follow-up measurements to
describe any characteristics related to missingness that are
able to be observed.
We will be analysing our data using an intention-to-
treat analysis. All randomised patients will be included
in the analysis, assuming non-informative censoring for
those withdrawn from the study or lost to follow-up for
the primary analysis.
During statistical data review and analysis, any anom-
alies in the data will be investigated and discussed with
the trial management team. The data investigation will
be broad and flexible and focus on variability of the data,
consistency, dispersion, outliers, inliers, relationships be-
tween variables, and relationships over time. The statis-
tical data review will be fully documented with all the
output dated. If fraud is proved, fraudulent data will be
removed from the analysis.
A full detailed analysis plan, including approach of
handling missing data, subgroup analyses, and sensitivityanalyses, and a plan for interim analysis will be prepared
before the first interim analysis by a statistician who is in-
dependent from the study. All analyses will be performed
by the trial statistician and validated by a separate statisti-
cian. A senior statistician will provide supervision to all
statistical aspects in the trial.
Health economics analysis
The economic evaluation will compare the implementa-
tion of ARA plus routine care with routine care for
CKD patients. We plan to conduct a within-trial eco-
nomic analysis. A within-trial cost-consequence analysis
will initially be reported, describing all the important re-
sults relating to the health care resource use, costs, and
consequences of ARA plus routine care compared with
routine care for CKD patients. Subsequently, a within-
trial cost-effectiveness analysis will consider cost per
additional primary endpoint (mortality and onset of
CVD) averted, and a cost-utility analysis will determine
cost per quality-adjusted life year (QALY) gained.
If trial results demonstrate clinical effectiveness, ex-
trapolation beyond the trial period of 36 months will be
undertaken. The methods used will depend on the within
trial data, but will either use parametric methods as set
out by the NICE Decision Support Unit [52] or use a life-
time decision-model (developing a Markov model or
adapting a CKD model), where available, to determine the
long-term cost-effectiveness of the intervention in terms
of cost per QALY gained. For both the within trial analysis
and the model, extensive deterministic sensitivity analysis
will be undertaken to assess the impact of changing the
key data and will be used to explore the importance of
modelling assumptions. Probabilistic sensitivity analyses
will be conducted to deal with uncertainty in model pa-
rameters and cost-acceptability curves presented.
Data monitoring
BARACK D will have a DMEC, who will report to and
advise the TSC who, in turn, will report to and advise
the trial management group. Both the DMEC and TSC
will have independent chairs and “stop rule” authority to
advise early termination of the trial in the event of safety
concerns or futility due to poor recruitment, lack of
events, or lack of any treatment effect (“stop rules” to be
defined by the DMEC).
Interim analysis
An internal pilot will be conducted which, in addition to
testing study procedures and documentation, will test
our assumptions regarding:
i. Practice uptake of the invitation to participate;
ii. Rates of eligible CKD patients in practice
populations on existing disease registers;
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iv. The rates of consent at baseline visits.
These early recruitment data will be used after 4 months
to determine whether any changes are needed to overall
recruitment strategy in the other centres, e.g., whether
numbers of practice sites need to be supplemented.
A formal futility analysis will be performed at 12 months
from first study recruitment with possible termination for
safety or futility. “Stop rules” will be defined fully by the
DMEC.
Harms
Procedures for recording AEs
All site staff will be appropriately trained in the proce-
dures to follow and the forms to use by the PC-CTU
prior to study initiation. Regular central monitoring for
all studies and site monitoring, as determined by the
trial-specific risk assessment, will be used to ensure that
all AEs are identified and acted on appropriately.
All AEs will be recorded at trial visits for the initial
6 months of follow-up by the member of the research
team conducting that visit for the previous inter-visit
period. Following this initial 6 month period, only the
following AEs will be monitored by the member of the
research team performing that visit in accordance with
PC-CTU SOPs:
 Enlargement of breasts in men and women
 Erectile dysfunction
 Irregular periods
 Vaginal bleeding after the menopause
 Deepening of the voice in women, change in the
tone of voice in men
 Excessive hair growth
 Tiredness
 Palpitations
 Numbness and tingling
AEs considered related to the study medication as
judged by a medically qualified member of the research
team or the sponsor will be followed until resolution or
the event is considered stable, clinically insignificant, or
asymptomatic. All related AEs that result in a partici-
pant’s withdrawal from the study or are present at the
end of the study, should be followed-up until a satisfac-
tory resolution occurs.
It will be left to the recruiting clinician’s clinical judg-
ment whether or not an AE is of sufficient severity to re-
quire the participant’s removal from treatment and, if
treatment is withdrawn, the reason will be recorded. A
participant may also voluntarily withdraw from treatment
due to what he or she perceives as an intolerable AE. If ei-
ther of these occurs, the participant must undergo an endof study assessment and be given appropriate care under
medical supervision until symptoms cease or the condi-
tion becomes stable.
 The severity of events will be assessed on the
following scale: 1 = mild, 2 = moderate, 3 = severe.
 The relationship of AEs to the study medication will
be assessed by a medically qualified member of the
research team.
Auditing
The study will be conducted in accordance with the
current approved protocol, International Conference on
Harmonisation Good Clinical Practice (ICH GCP), rele-
vant regulations, and PC-CTU SOPs. The PC-CTU has
in place procedures for assessing risk management for
trials which will outline the monitoring required. The
monitoring will be carried out by the PC-CTU Quality
Assurance Manager or equivalent. The investigators and
all trial related site staff will receive appropriate training
in GCP and trial procedures.
Regular monitoring will be performed according to
ICH GCP using a risk-based approach. Data will be eval-
uated for compliance with the protocol and accuracy in
relation to source documents where possible. Following
written SOPs, the monitors will verify that the clinical
trial is conducted and data are generated, documented,
and reported in compliance with the protocol, GCP, and
the applicable regulatory requirements. The Study Moni-
tor may also assess serious AEs.
Ethics and dissemination
Declaration of Helsinki
The research team will ensure that this study is conducted
in accordance with the principles of the Declaration of
Helsinki 1964 (and subsequent revisions).
ICH guidelines for GCP
The research team will ensure that this study is conducted
in full conformity with relevant regulations and with the
ICH Harmonised Tripartite Guidelines for Good Clinical
Practice (CPMP/ICH/135/95) July 1996.
Approvals
The protocol, informed consent form, participant infor-
mation sheet, any further patient facing documents and
any proposed advertising material have been submitted
to an appropriate Research Ethics Committee (REC -
13/SC/0114), the Medicines and Healthcare Regulatory
Authority (MHRA in the UK), the relevant NHS Re-
search and Development Departments, and host institu-
tion for written approval. The research team will submit
and, where necessary, obtain approval from the above
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proved documents.
Protocol amendments
Any modifications to the protocol which may impact on
the conduct of the study, potential benefit of the patient
or may affect patient safety, including changes of study
objectives, study design, patient population, sample sizes,
study procedures, or significant administrative aspects
will require a formal amendment to the protocol. Such
amendment will be agreed upon by the sponsor, and ap-
proved by the Ethics Committee prior to implementa-
tion and notified to the health authorities in accordance
with local regulations.
Administrative changes of the protocol are minor cor-
rections and/or clarifications that have no effect on the
way the study is to be conducted. These administrative
changes will be agreed upon by the sponsor, and will be
documented in a memorandum. The Ethics Committee
may be notified of administrative changes. Previous
amendments and protocol versioning are available in on-
line Additional file 1.
Consent or assent
Informed consent will be taken according to PC-CTU
SOPs. A Patient Information Leaflet will be given by the
research team to the patient following identification as a
potential participant. This leaflet describes the purpose
of the study, explains in detail what is required of partic-
ipants, discusses potential risks and benefits, and pro-
vides contact details for the research team. The patient
will be given adequate time to consider participation and
read the leaflet, consulting with family or friends or any
other independent advisors if needed, before seeing the
research team for the first study consultation. At the
baseline assessment informed consent will be taken, by a
suitably qualified member of the research team, who will
have received training in GCP and will be authorised to
take consent by the Chief Investigator, delegated through
the Principal Investigators where applicable. The Con-
sent Form will be signed and dated both by the patient
and the member of the research team taking consent.
No study related procedures will take place prior to the
signing of the consent form. It is clearly stated that the
participant is free to withdraw from the study at any
time for any reason without prejudice to future care, and
with no obligation to give a reason for withdrawal. If the
patient requires more time to make a decision on par-
ticipation then a further consultation will be arranged.
Participants will be asked to consent to being contacted
by the research team in the event they fail to return for
any of the trial follow-up. Consented participants will be
asked to complete a Contact Details Form which in-
cludes all of their relevant contact details and indicationas to their preferred method of contact by the research
team. A copy of the signed consent form will be given to
the participant and a further copy will be sent with the
Contact Details Form to the research team. One copy of
the consent will remain in the patient’s records at the re-
cruitment site.
Consent will be taken to allow relevant sections of pa-
tient medical notes and data collected during the study
to be looked at by responsible individuals from the par-
ticipating centres, regulatory authorities (including the
MHRA), and the NHS Trust, where it is relevant to tak-
ing part in the trial.
Patients declining to participate will be asked if they
are willing to provide separate written consent to review
their records for comparative data. Data will be manually
recorded in a separate CRF and transferred to the trial
database.
Ancillary studies
Where transport and local coordination allows an add-
itional blood and urine sample will be taken and stored
for future genetic and protein testing.
Confidentiality
Ensuring patient confidentially is an established and ro-
bust process within the PC-CTU. All staff adhere to the
principles of GCP and the Data Protection Act, 1998.
It is the PC-CTU’s preferred procedure that patients
will only be identified on study documents by use of a
unique study ID which cannot be used to identify indi-
vidual participants. Where this is not possible, specific
consent will be taken and participants contact details
will be used in order of their preference, e.g., when ne-
cessary to make follow-up phone calls or emails. All
study documents, such as CRFs, holding patient infor-
mation are held securely with restricted access either
electronically or in paper format.
CRFs and all other documents holding identifiers are
anonymised as soon as possible with the process of man-
agement being outlined in detail within the ethics appli-
cation and in trial specific procedures. The holding of
patient identifiers is noted, as a trial specific vulnerability
in the risk assessment and the Chief Investigator is re-
quired to clearly outline how such risks will be managed,
to minimise both likelihood and impact and how the suc-
cess of the management will be monitored and assessed.
Access to data
The PC-CTU will oversee the intra-study data sharing
process, with input from the DMEC. All Principal Inves-
tigators will be given access to the cleaned data sets. All
data sets will be password protected. To ensure confi-
dentiality, data dispersed will be blinded of any identify-
ing participant information.
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In this population of patients it is thought that if there is
no reason to withdraw the ARA from the patient then
GPs should keep prescribing it if they wish to.
Dissemination policy
Trial results
The investigators will be involved in reviewing drafts of
the manuscripts, abstracts, press releases, and any other
publications arising from the study. Authors will ac-
knowledge that the study was funded by the National
Institute for Health Research Health Technology Assess-
ment Programme. Reporting will adhere to CONSORT
guidelines [53].
Authorship
Authorship will be determined in accordance with the
International Committee of Medical Journal Editors guide-
lines and other contributors will be acknowledged.
Reproducible research
The WHO dataset is available in online Additional file 1.
There are no plans to make the data open source.
Roles and responsibilities
Sponsor
Trial sponsor: University of Oxford
Sponsors Reference: Lock code 107072/414895/1/743
Contact name: Ms Heather House
Address: Research Services, CTRG, Joint Research
Office, Block 60, Churchill Hospital, Headington, OX3 7LE
Telephone: +44 (0)1865 572224
Email: heather.house@admin.ox.ac.uk
Committees
The PC-CTU Trial Management Committee will be re-
sponsible for the monitoring of all aspects of the trial’s
conduct and progress and will ensure that the protocol
is adhered to and that appropriate action is taken to
safeguard participants and the quality of the trial itself.
The Trial Management Committee will be comprised of
individuals responsible for the trial’s day to day manage-
ment (e.g., the Chief Investigator, trial manager, statisti-
cian, data manager) and will meet regularly throughout
the course of the trial.
A TSC will be convened to provide overall supervision
of the trial and ensure its conduct is in accordance with
the principles of GCP and the relevant regulations. The
TSC will review the trial protocol, be notified of any
protocol amendments, and provide advice to the investi-
gators on all aspects of the trial. The TSC will consist of
members who are independent of the investigators, in
particular an independent chairperson.An independent DMEC will review the accruing trial
and safety data to ensure trial site staff and participants
are aware of any relevant safety information and to de-
termine whether any reasons exist for the trial to be
discontinued.
An independent, blinded Endpoint Committee (blinded
to the treatment arm) will adjudicate primary endpoints.
Discussion
Desirable clinical outcomes for any new therapies would
be the effective and safe reduction of cardiovascular
events and premature death and/or delay in progression
of renal decline. The most important target CKD popu-
lation for such preventive interventions are those with
CKD stage 3b (eGFR 30–44 mL/min/1.73 m2), since this
has a prevalence at about 1% [1,2], represents progres-
sive renal disease, and is associated with a 12-fold in-
crease in CVD compared to those with eGFR above
60 mL/min/1.73 m2 [13]. In contrast, relative cardiovas-
cular risk is only 2-fold in patients with CKD stage 3a
(eGFR 45–59 mL/min/1.73 m2) [13], though the preva-
lence is near 5% [1,2].
In addition to relative CVD risk reduction, there are
limited therapeutic options for the prevention of further
renal functional decline in patients with CKD. Presently,
the only interventions shown to reduce or prevent renal
function decline for most patients with CKD is avoid-
ance of renal damage (e.g., treating infections and avoid-
ing NSAIDs in at-risk people), and effective treatment of
risk factors, namely hypertension and diabetes. In
addition, drugs acting on the RAAS system offer modest
additional benefits to BP lowering alone in patients with
diabetic nephropathy with proteinuria [33].
The BARACK D trial evaluates beneficial effects and
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